Glomerulonephritis chronic – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 23 Jun 2026 04:04:18 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Glomerulonephritis chronic – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Stopping Rituximab vs. Continuing Rituximab for Patients with ANCA-Associated Vasculitis in Stable Remission https://clinicaltrials.eu/trial/study-on-stopping-rituximab-vs-continuing-rituximab-for-patients-with-anca-associated-vasculitis-in-stable-remission/ Wed, 29 Apr 2026 14:28:09 +0000 https://clinicaltrials.eu/trial/study-on-stopping-rituximab-vs-continuing-rituximab-for-patients-with-anca-associated-vasculitis-in-stable-remission/ This clinical trial is focused on studying a condition known as ANCA-associated vasculitis, which is a type of inflammation that affects blood vessels. The study is examining the effects of a medication called rituximab, which is often used to help manage this condition. The purpose of the study is to compare the outcomes of patients who continue using rituximab with those who stop using it, to see how it affects the likelihood of the disease returning.

Participants in the study will be randomly assigned to either continue with rituximab treatment or to discontinue it. The study will monitor the participants over a period of time to observe any changes in their condition, particularly focusing on whether the disease comes back. The study will also look at other factors such as kidney function, overall health quality, and any side effects experienced during the trial.

The trial aims to provide valuable information on the best approach to managing ANCA-associated vasculitis in patients who are in stable remission. By understanding the effects of continuing or stopping rituximab, the study hopes to improve treatment strategies for this condition.

]]>